These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

989 related items for PubMed ID: 26281972

  • 1. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P, Sugimoto D, Vlajnic A, Kilo C.
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [Abstract] [Full Text] [Related]

  • 2. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF, Traylor L, Schwartz SL.
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [Abstract] [Full Text] [Related]

  • 3. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, Park JY.
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [Abstract] [Full Text] [Related]

  • 5. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU, Plewe G, Busch K.
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.
    Park CY, Kang JG, Chon S, Noh J, Oh SJ, Lee CB, Park SW.
    PLoS One; 2014 Feb; 9(3):e87799. PubMed ID: 24614911
    [Abstract] [Full Text] [Related]

  • 8. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.
    Ann Intern Med; 2008 Oct 21; 149(8):531-9. PubMed ID: 18936501
    [Abstract] [Full Text] [Related]

  • 9. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.
    Diabetes Care; 2005 Feb 21; 28(2):254-9. PubMed ID: 15677775
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C.
    Diabetes Obes Metab; 2015 Dec 21; 17(12):1133-41. PubMed ID: 26085028
    [Abstract] [Full Text] [Related]

  • 12. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.
    Jermendy G, Hungarian RECAP Group, Erdesz D, Nagy L, Yin D, Phatak H, Karve S, Engel S, Balkrishnan R.
    Health Qual Life Outcomes; 2008 Oct 31; 6():88. PubMed ID: 18976457
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S, Taskinen MR, Owens DR, von Eynatten M, Emser A, Gong Y, Chiavetta S, Patel S, Woerle HJ.
    J Diabetes Complications; 2013 Oct 31; 27(3):274-9. PubMed ID: 23403068
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
    Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T.
    Diabetes Obes Metab; 2016 Apr 31; 18(4):366-74. PubMed ID: 26662838
    [Abstract] [Full Text] [Related]

  • 19. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.
    Diabetes Obes Metab; 2015 Jan 31; 17(1):15-22. PubMed ID: 24957785
    [Abstract] [Full Text] [Related]

  • 20. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR, Traylor L, Mullins P, Landgraf W.
    Diabetes Res Clin Pract; 2017 Feb 31; 124():57-65. PubMed ID: 28092788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.